mozavaptan

Mozavaptan is an orally active, selective, competitive vasopressin V2 receptor antagonist and a benzazepine derivative. It works by inhibiting the binding of vasopressin (antidiuretic hormone, ADH) to V2 receptors located in the renal collecting ducts. This antagonistic action prevents water reabsorption, leading to increased free water excretion, a process known as aquaresis, without significant loss of electrolytes. Mozavaptan is primarily used to manage conditions associated with water retention and electrolyte imbalances, such as hyponatremia, particularly that caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). It has also been investigated for its potential in treating chronic heart failure and liver cirrhosis. It was developed by Otsuka Pharmaceutical Co., Ltd. and approved in Japan for paraneoplastic SIADH.

Brand names

Mozavaptan

Other names

mozavaptan hydrochloridemozavaptan HCl